FY2025 Earnings Forecast for MNPR Issued By Chardan Capital

Key Points

• Chardan Capital has revised its FY2025 earnings per share estimate for Monopar Therapeutics to ($1.93), an improvement from the previous estimate of ($2.02), while maintaining a "Buy" rating and a target price of $60.00.
• The consensus estimate for Monopar's full-year earnings currently stands at ($1.65) per share, indicating that Chardan's forecast remains more conservative than the market consensus.
• Recently reported earnings showed Monopar Therapeutics beating expectations with ($0.35) earnings per share for the quarter, surpassing the consensus estimate of ($0.47).

Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) - Research analysts at Chardan Capital raised their FY2025 earnings estimates for shares of Monopar Therapeutics in a research note issued on Wednesday, August 13th. Chardan Capital analyst K. Nakae now forecasts that the company will post earnings per share of ($1.93) for the year, up from their prior forecast of ($2.02). Chardan Capital has a "Buy" rating and a $60.00 price target on the stock. The consensus estimate for Monopar Therapeutics' current full-year earnings is ($1.65) per share. Chardan Capital also issued estimates for Monopar Therapeutics' FY2026 earnings at ($3.01) EPS.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last issued its earnings results on Tuesday, August 12th. The company reported ($0.35) EPS for the quarter, topping analysts' consensus estimates of ($0.47) by $0.12.

MNPR has been the topic of a number of other research reports. Cantor Fitzgerald began coverage on shares of Monopar Therapeutics in a research report on Monday, July 7th. They issued an "overweight" rating and a $74.00 target price on the stock. Wall Street Zen raised shares of Monopar Therapeutics from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. Five analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $60.00.

Monopar Therapeutics Stock Performance

NASDAQ:MNPR traded up $0.35 during trading hours on Monday, reaching $33.35. The company's stock had a trading volume of 34,496 shares, compared to its average volume of 39,685. The firm has a market capitalization of $205.77 million, a price-to-earnings ratio of -10.08 and a beta of 1.05. The firm has a 50-day simple moving average of $37.96 and a 200-day simple moving average of $37.66. Monopar Therapeutics has a 1 year low of $2.25 and a 1 year high of $54.30.

Insider Activity

In other news, CEO Chandler Robinson sold 16,800 shares of the stock in a transaction on Monday, July 14th. The shares were sold at an average price of $40.00, for a total value of $672,000.00. Following the sale, the chief executive officer owned 73,472 shares of the company's stock, valued at approximately $2,938,880. This represents a 18.61% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Christopher M. Starr sold 16,800 shares of the stock in a transaction on Monday, July 14th. The shares were sold at an average price of $40.00, for a total transaction of $672,000.00. Following the completion of the sale, the director directly owned 5,173 shares in the company, valued at approximately $206,920. This represents a 76.46% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 42,504 shares of company stock valued at $1,700,160. 20.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Monopar Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of Monopar Therapeutics in the second quarter valued at $80,000. Affinity Asset Advisors LLC raised its stake in shares of Monopar Therapeutics by 8.9% in the second quarter. Affinity Asset Advisors LLC now owns 67,500 shares of the company's stock valued at $2,415,000 after acquiring an additional 5,500 shares during the period. New York State Common Retirement Fund purchased a new position in Monopar Therapeutics in the 2nd quarter worth about $104,000. Rhumbline Advisers purchased a new position in Monopar Therapeutics in the 2nd quarter worth about $209,000. Finally, JPMorgan Chase & Co. increased its stake in Monopar Therapeutics by 1,821.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company's stock worth $69,000 after buying an additional 1,821 shares during the period. Hedge funds and other institutional investors own 1.83% of the company's stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.